Similarly, the CLARIFY registry which started in 2009 reported better secondary prevention in patients with CKD and CAD with more than 75% of all patients taking ACE inhibitors or angiotensin-receptor blockers, 95% taking antiplatelet medication, and—comparable to our findings—84% taking statins [18]. This evidence concerns the gene ACE and coronary artery disorder.